Gilead Sciences INC (GILD) Holder Obermeyer Wood Investment Counsel Lllp Trimmed Holding as Market Valuation Rose

May 26, 2018 - By Marie Mckinney

Gilead Sciences, Inc. (NASDAQ:GILD) LogoInvestors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It dropped, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Arcadia Investment Mngmt Corporation Mi reported 0.02% in Gilead Sciences, Inc. (NASDAQ:GILD). Gradient Invests Limited Company holds 0% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 501 shares. Zwj Counsel Inc stated it has 1.39% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Chevy Chase Hldgs invested in 0.35% or 1.14M shares. Amg National Trust Bancorporation owns 29,923 shares for 0.14% of their portfolio. 1,049 were accumulated by Private Ocean Limited Liability. Hermes Inv Management Ltd holds 22,016 shares or 0.02% of its portfolio. Rock Springs Cap Management Limited Partnership has invested 1.02% in Gilead Sciences, Inc. (NASDAQ:GILD). 135,997 are owned by Ontario Teachers Pension Plan Board. Supplemental Annuity Collective Trust Of Nj reported 17,000 shares or 0.51% of all its holdings. Ahl Llp has invested 0.13% in Gilead Sciences, Inc. (NASDAQ:GILD). Profund Advsrs Limited Liability Corporation invested 1.56% in Gilead Sciences, Inc. (NASDAQ:GILD). Macquarie owns 395,154 shares or 0.05% of their US portfolio. Hexavest invested in 476,038 shares or 0.39% of the stock. Old Mutual Glob (Uk) Ltd owns 0.01% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 16,819 shares.

Since January 2, 2018, it had 0 buys, and 22 selling transactions for $44.80 million activity. The insider Alton Gregg H sold 30,000 shares worth $2.37M. Another trade for 5,000 shares valued at $401,566 was sold by Washington Robin L. MARTIN JOHN C also sold $3.93M worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares. Meyers James R also sold $8.02M worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares. WILSON GAYLE E sold $4.68M worth of stock or 60,000 shares.

Obermeyer Wood Investment Counsel Lllp decreased its stake in Gilead Sciences Inc (GILD) by 14.7% based on its latest 2017Q4 regulatory filing with the SEC. Obermeyer Wood Investment Counsel Lllp sold 45,593 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 264,492 shares of the health care company at the end of 2017Q4, valued at $18.95 million, down from 310,085 at the end of the previous reported quarter. Obermeyer Wood Investment Counsel Lllp who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $87.61B market cap company. The stock decreased 0.22% or $0.15 during the last trading session, reaching $67.38. About 3.96 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since May 26, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 25. They expect $1.43 EPS, down 43.03 % or $1.08 from last year’s $2.51 per share. GILD’s profit will be $1.86 billion for 11.78 P/E if the $1.43 EPS becomes a reality. After $1.37 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts 4.38 % EPS growth.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Gilead: I’m Thankful That I Sold” on May 07, 2018, also Bizjournals.com with their article: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” published on May 17, 2018, 247Wallst.com published: “Short Interest Remains Mixed in Major Biotechs” on May 25, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Bizjournals.com and their article: “He helped Gilead score billions from HIV, hepatitis C drugs — now he’s building a cancer fighter” published on May 23, 2018 as well as 247Wallst.com‘s news article titled: “Analysts Show More Caution Toward Gilead’s Mystical Recovery” with publication date: May 02, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 14 analysts covering Gilead Sciences (NASDAQ:GILD), 8 have Buy rating, 0 Sell and 6 Hold. Therefore 57% are positive. Gilead Sciences had 24 analyst reports since November 30, 2017 according to SRatingsIntel. On Wednesday, January 3 the stock rating was maintained by Credit Suisse with “Hold”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Outperform” rating by Wells Fargo on Tuesday, January 16. Maxim Group upgraded the shares of GILD in report on Thursday, November 30 to “Buy” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Equal-Weight” rating by Morgan Stanley on Wednesday, February 7. On Wednesday, May 2 the stock rating was maintained by Barclays Capital with “Overweight”. The firm earned “Hold” rating on Wednesday, May 2 by Leerink Swann. Credit Suisse downgraded the shares of GILD in report on Wednesday, December 20 to “Neutral” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Wednesday, February 7 by RBC Capital Markets. The company was maintained on Wednesday, February 7 by Bank of America. Citigroup upgraded the stock to “Buy” rating in Tuesday, January 30 report.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: